profit from every $100 of sales.
$0$100
Alumis
$6.55+8.62% today
-37.5% in 1 year
1-year low $5.851-year high $30.30
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Alumis sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $24.1 million in 2025, with -$243 million of profit last year.
SalesProfit
Alumis vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Alumis | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Alumis's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 24 | |
| – | – | – | – | |
| -114 | -158 | -301 | -454 | |
| -114 | -157 | -298 | -450 | |
| -112 | -155 | -294 | -243 | |
| -2.91 | -2.99 | -10.38 | -2.32 | |
| – | – | – | – | |
| – | – | – | -1,886.9% | |
| – | – | – | -1,011.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 108 | 90 | 341 | 412 |
| Cash | 26 | 46 | 170 | 90 |
| Total debt | 2 | 33 | 31 | 37 |
| Total liabilities | 303 | 429 | 81 | 111 |
| -195 | -339 | 260 | 301 | |
| 38 | 52 | 28 | 105 | |
| – | – | -81.7% | -106.0% | |
| 57.3% | 45.7% | -113.1% | -80.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -108 | -130 | -255 | -370 | |
| 2 | 4 | 2 | 1 | |
| -110 | -134 | -257 | -370 | |
| Dividends paid | – | – | – | – |
| – | 0 | – | – | |
| 6 | 9 | 19 | 44 |
Valuation
- –
- –
- –
- 5.0×
- 35.3×
- –
- –
- -43.7%
- -28.7%
- 0.0%
Profitability
- 89.6%
- -1,886.9%
- -1,011.7%
- -5,087.6%
- -71.9%
- -16.2%
- -54.6%
- -35.4%
- -75.0%
- 4,404.2%
Growth
- –
- –
- −44.1%
- –
- +384.0%
Financial health
- -0.1×
- 0.06
- 5.3%
- –
- 7.51
- 7.51
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 948
Bottom 1%of 985
What analysts expect
- Average price target
- $38.44
- Range
- $32.00 – $50.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.74 | -0.73 | −1.1% |
| Mar 19, 2026 | -0.95 | -0.97 | +2.1% |
| Nov 13, 2025 | -1.06 | -0.92 | −15.2% |
| Aug 13, 2025 | -1.17 | -1.11 | −5.4% |
| May 14, 2025 | -1.82 | -1.47 | −23.8% |
| Mar 19, 2025 | -0.23 | -1.40 | +83.6% |
| Nov 13, 2024 | -1.73 | -1.64 | −5.5% |
| Aug 13, 2024 | -23.10 | -4.50 | −413.3% |
News
Alumis downgraded at Guggenheim after trial setback for SLE candidateSeeking Alpha · Sep 3, 2026The newest story we have is from Sep 3, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/6Passes 3 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
42No pass
Philip Fisher
65Pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
67Pass
Terry Smith
63Pass
Questions about Alumis
Is Alumis a good stock to buy?
A business with weak numbers that is not profitable yet. 3 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Alumis AI analysis
What does Alumis do?
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It is in Biotechnology, based in South San Francisco, CA, United States, with 225 employees.
Does Alumis pay a dividend?
No. Alumis does not pay a dividend at the moment.
Is Alumis stock halal?
No. Alumis does not pass our halal screen: its cash and confirmed interest-bearing investments are 36% of its market value, at or above the 33% limit. How we check
How has Alumis stock done over the past year?
Down 37.5% over the past twelve months, to $6.55. It traded between $5.85 and $30.30 and is 78.4% below its high.
Who are Alumis's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Alumis's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.